Blockbusters like Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. Time has now come for the next leap forward in the treatment of acid related diseases. Cinclus Pharmaâs clinical stage drug candidate X842 takes a new approach to provide improved management of esophagitis and GERD symptoms.
Location: Sweden, Stockholm
Total raised: $26.47M
Investors 2
| Date | Name | Website |
| 23.07.2023 | Irrus Inve... | irrusinves... |
| - | Eir Ventur... | eirventure... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.03.2020 | - | $26.47M | - |
Mentions in press and media 10
| Date | Title | Description |
| 10.09.2026 | Claret Capital Secures €575M for European Tech, Life Sciences Growth | Claret Capital Partners has finalized its €575 million Fund IV. This significant growth debt fund targets Europe's burgeoning technology and life sciences sectors. It provides flexible, non-dilutive capital. The firm exceeded its €500 milli... |
| 07.09.2026 | Claret Capital Partners exceeds target with €575M growth debt fund for European innovators | Claret Capital Partners has closed its fourth European Growth Capital Fund at €575 million, exceeding its €500 million target. Including affiliated discretionary mandates, the fund will make growth debt investments in technology, life scien... |
| 07.09.2026 | Claret Capital Partners Raises €575M for European Growth | Claret Capital Partners Closes €575M Fund IV London-based Claret Capital Partners has raised €575 million through Fund IV and an affiliated discretionary mandate. This surpassed its original €500 million fundraising target. The firm complet... |
| 20.06.2024 | Trading in Trill Impact’s portfolio company Cinclus Pharma commences on Nasdaq Stockholm | Trading in Trill Impact’s portfolio company Cinclus Pharma commences on Nasdaq Stockholm Thu, Jun 20, 2024 08:10 CET Report this content The Swedish biopharmaceutical company has successfully raised capital for Phase 3 clinical development ... |
| 20.05.2022 | Trill Impact leads the 240 MSEK venture financing round in Cinclus Pharma | Trill Impact leads the 240 MSEK venture financing round in Cinclus Pharma Fri, May 20, 2022 08:00 CET Report this content Trill Impact leads a 240 MSEK venture financing round in Cinclus Pharma AB, a Swedish late-stage biopharmaceutical com... |
| 29.11.2021 | Cinclus Pharma Appoints Gösta Hiller as Chief Operating Officer | Cinclus Pharma Appoints Gösta Hiller as Chief Operating Officer Mon, Nov 29, 2021 08:00 CET Stockholm, Sweden: Cinclus Pharma Holding AB (“Cinclus Pharma”), a biopharmaceutical company focused on the development of a novel treatment for gas... |
| 06.09.2021 | Cinclus Pharma receives approval of the International Nonproprietary Name (INN) linaprazan glurate for its lead drug candidate for the treatment of GERD | Cinclus Pharma receives approval of the International Nonproprietary Name (INN) linaprazan glurate for its lead drug candidate for the treatment of GERD Mon, Sep 06, 2021 14:00 CET Stockholm, Sweden: Cinclus Pharma Holding AB (“Cinclus Phar... |
| 27.08.2021 | Cinclus Pharma Appoints Maria Engström as Chief Financial Officer | Cinclus Pharma Appoints Maria Engström as Chief Financial Officer Fri, Aug 27, 2021 08:00 CET Stockholm, Sweden: Cinclus Pharma Holding AB (“Cinclus Pharma”), a biopharmaceutical company focused on the development of a novel treatment for g... |
| 18.08.2021 | Cinclus Pharma announces the first patient randomized in the Phase II study for X842 in GERD. | Cinclus Pharma announces the first patient randomized in the Phase II study for X842 in GERD. Wed, Aug 18, 2021 11:00 CET Stockholm, Sweden: Cinclus Pharma Holding AB (“Cinclus Pharma”), a biopharmaceutical company focused on the developmen... |
| 05.03.2020 | Cinclus Pharma Raises SEK250M in Funding | Cinclus Pharma Holding AB, a Swedish developer of a novel treatment against gastroesophageal reflux disease, raised SEK250M in funding. The Fourth Swedish National Pension Fund (AP4) joined as a new major shareholder through the issue, whic... |